An observational study in Gender Differences, Adherence, Medication and Therapeutic Adherence, sponsored by Spanish Society of Cardiology. Completed at 25 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Spanish Society of Cardiology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Medication Adherence with a site in Spain — 4 open to participants now, 5 under way, none of them phase 3. Medication Adherence · Spain.
Among the 23 studies in Medication Adherence with a site in Spain, this one is the only one that started in 2023, is one of 6 observational ones, and was the 16th registered.
943 studies on the registry are indexed under Medication Adherence; 162 are open to participants now.
Browse Medication Adherence studies →4 of the 23 studies in Medication Adherence with a site in Spain are open now. Recruiting first, the newest first:
Fundació Sant Joan de Déu · Sites in Spain
Ages 18–65
Corporacion Parc Tauli · Sites in Spain
Ages 18–75
Consorci Sanitari de l'Alt Penedès i Garraf · Sites in Spain
Ages 18+
Hospital San Carlos, Madrid · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 81 Medication Adherence studies recruiting now, 52 (64%) set no upper age limit and 21 (26%) stop at 75 or younger; 15 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2023.
This study's enrollment of 530 is above the median of 250 across 149 observational studies indexed under Medication Adherence.
Median enrollment 179 across the 17 interventional studies, 565 across the 6 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 23 have an industry lead sponsor. The 10 most frequent:
Spanish Society of Cardiology is the lead sponsor of 23 studies on the registry; 6 are open to participants now.
Spanish Society of Cardiology has 1 study filed under Medication Adherence — fewer than ten, so there is no comparison to draw.
1 of the studies in Medication Adherence with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07946523Fundació Sant Joan de DéuAndy's Mind: A Co-created Serious Game for People With Psychosis (PSICOGAME) | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Medication Adherence with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
PARTICIPANT CENTERS: 25 hospitals managing routinely acute myocardial infarction (AMI) and representing different regions from Spain will be invited to participate.
GENERAL OBJECTIVE: To evaluate if there are differences in the level of adherence to recommended secondary prevention therapies (pharmacological and non-pharmacological) between women and men surviving a type 1 acute myocardial infarction (with obstructive coronary artery disease), its potential consequences, and the potential factors related to that difference, if present.
DESIGN:
Prospective, matched cohort study of patients hospitalized for a type 1 acute myocardial infarction with evidence of obstructive coronary artery disease who are discharged home alive. Women will be enrolled first, ideally in a consecutive manner, as they are the focus of the study. Men will be recruited subsequently as the comparison group, with 1:1 matching for age and ECG presentation. Matching will be performed locally, in each study site (hospital). All patients will undergo 1-year follow-up with clinical and therapeutic adherence evaluation.
- Reference cohort: 500 women discharged alive after a hospitalization for a type 1 acute myocardial infarction with significant coronary artery disease.
- Comparator cohort: 500 age (±2 years) and ECG (ST-segment elevation acute myocardial infarction (STEMI) / non-ST-segment elevation acute myocardial infarction (NSTEMI)) locally matched men discharged alive after a hospitalization for a type 1 acute myocardial infarction with significant coronary artery disease.
OBJECTIVES
General objective: To evaluate if there are differences in the level of adherence to recommended secondary prevention therapies (pharmacological and non-pharmacological) between women and men surviving a type 1 acute myocardial infarction (with obstructive coronary artery disease), its potential consequences, and the potential factors related to that difference, if present.
Specific objectives: To compare between women and men:
1) The adherence to recommended secondary prevention therapies at 6 months and 12 months measured as the:
1a. Proportion of patients adherent to all recommended pharmacological secondary prevention therapies at 6 and 12 months.
1b. Proportion of patients adherent to all recommended non-pharmacological secondary prevention therapies at 6 and 12 months.
2) The relationship of the adherence with control of risk factors, clinical outcomes, and use of healthcare resources.
2a. The proportion of patients with optimal control of all cardiovascular risk factors at 6 and 12 months.
2b. The incidence of clinical outcomes at 6 and 12 months. 2c. The cumulative use of healthcare resources and cost after discharge.
3) To assess the factors associated with non-adherence to recommended secondary prevention therapies, with special emphasis to socioeconomic factors and gender issues.
STUDY DESIGN
DESIGN:
Prospective, matched cohort study of patients hospitalized for a type 1 acute myocardial infarction with evidence of obstructive coronary artery disease who are discharged home alive. Women will be enrolled first, ideally in a consecutive manner, as they are the focus of the study. Men will be recruited subsequently as the comparison group, with 1:1 matching for age and ECG presentation. Matching will be performed locally, in each study site (hospital). All patients will undergo 1-year follow-up with clinical and therapeutic adherence evaluation.
RECRUITMENT:
Participant centers:
25 hospitals managing routinely acute myocardial infarction and representing different regions from Spain will be invited to participate.
Patient recruitment:
All consecutive women fulfilling all inclusion criteria and without exclusion criteria surviving the index hospitalization will be invited to participate. Subsequently, men with inclusion criteria and without exclusion criteria, matched for age and ECG presentation, will be recruited.
STATISTICAL ANALYSIS:
A minimum sample size of 820 participants (410 per group) was estimated for an expected relative difference in recommendations compliance of the all-or-none composite primary outcome of 20%. An α error of 0.05 and a β error of 0.20 were considered for the sample size. The recommendations compliance was estimated as 42% for women and 52% for men. With the consideration of 20% of lost to follow-up (discontinuations) the total sample size is 984 patients, which is rounded out to 1000 patients (500 women and 500 men). To increase regional representation and allow exploration of potential regional variability, 25 hospitals from all regions in Spain (17 Autonomous Communities) will be invited to participate.
For the description of continuous variables, mean and standard deviation, or median and interquartile range will be used for Gaussian and non-normal distributions, respectively. For describing categorical variables, frequencies and percentages per category will be used. Categorical variables will be compared using the chi2 test, whilst continuous variables will be compared using the student t test.
Logistic regression models will be used to evaluate differences in binary outcomes between women and men (in hospital acute myocardial infarction management, post discharge myocardial infarction management). All subjects will be assumed to have a fixed follow-up (12±1 month). Multivariate adjusted models will be used to address any potential confounding in the associations between sex and each of the outcomes. Covariates will be selected based on their pre-defined clinical value and the unbalances observed across groups in the univariate analyses. Linear, multinomial or ordinal regression models would be used in case of continuous, categorical, or ordinal outcomes, respectively.
In addition to the models evaluating the association between sex and outcomes, a predictive model will be conducted to set predictors for the following outcomes:
For women-specific analysis, female specific factors (menarche age, pregnancies, gestational diabetes, menopause…) will be considered.
It will be used the Clinical Outcomes, HEalthcare REsource UtilizatioN, and relaTed costs (COHERENT) model to study the hospital-related healthcare resources (emergency department visits, specialist visits, re-hospitalizations and urgent procedures) and costs.
Prospective, matched cohort study of patients hospitalized for a type 1 AMI with evidence of obstructive coronary artery disease who are discharged home alive. Women will be enrolled first, ideally in a consecutive manner, as they are the focus of the study. Men will be recruited subsequently as the comparison group, with 1:1 matching for age and ECG presentation. Matching will be performed locally, in each study site (hospital). All patients will undergo 1-year follow-up with clinical and therapeutic adherence evaluation.
Reference cohort: 500 women discharged alive after a hospitalization for a type 1 AMI with significant CAD.
Comparator cohort: 500 age (±2 years) and ECG (STEMI/NSTEMI) locally matched men discharged alive after a hospitalization for a type 1 AMI with significant CAD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
500 women discharged alive after a hospitalization for a type 1 acute myocardial infarction with significant coronary artery disease.
500 age (±2 years) and ECG (STEMI/NSTEMI) locally matched men discharged alive after a hospitalization for a type 1 acute myocardial infarction with significant coronary artery disease.
Composite outcome of adherence to all secondary cardiovascular prevention recommendations at 12 months after discharge
The composite is built as an all-or-nothing response to an adherence ≥80% in all prescribed components of the endpoint: pharmacological therapies (MMAS-8), diet, physical activity and participation in a cardiac rehabilitation program. Adherence will be defined as having at least 80% compliance with all cardiovascular prevention recommendations; drugs, cardiac rehabilitation program, diet and physical activity)
Time frame: 12 months
Pharmacological primary endpoint
Outcome of adherence to pharmacological therapies (MMAS-8) 12 months after discharge
Time frame: 12 months
Non-pharmacological primary endpoint
Composite outcome of adherence to non-pharmacological secondary cardiovascular prevention recommendations 12 months after discharge, including diet, physical activity and participation in cardiac rehabilitation programs
Time frame: 12 months
Pharmacological primary endpoint
Outcome of adherence to pharmacological therapies (MMAS-8) 6 months after discharge
Time frame: 6 months
Non-pharmacological primary endpoint
Composite outcome of adherence to non-pharmacological secondary cardiovascular prevention recommendations 6 months after discharge, including diet, physical activity and participation in cardiac rehabilitation programs
Time frame: 6 months
Plan to share: No
Ran from Mar 2023 to primary completion in Jan 2026, 34 months.
Of 51 non-industry observational studies under Medication Adherence, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 64. This study's 34 months is close to that.
Counting every sponsor, half of 54 studies reached it within 32 months; a quarter within 12 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Spanish Society of Cardiology